Last Updated: June 9, 2026

List of Excipients in API atomoxetine hydrochloride


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing atomoxetine hydrochloride

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Eli Lilly and Company STRATTERA atomoxetine hydrochloride 0002-3227 DIMETHICONE
Eli Lilly and Company STRATTERA atomoxetine hydrochloride 0002-3227 GELATIN
Eli Lilly and Company STRATTERA atomoxetine hydrochloride 0002-3227 SODIUM LAURYL SULFATE
Eli Lilly and Company STRATTERA atomoxetine hydrochloride 0002-3227 STARCH, CORN
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Start Trial

Detailed excipient profiles for atomoxetine hydrochloride

Excipient focus: DIMETHICONE

Excipient focus: FD&C BLUE NO. 2

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GELATIN

Excipient focus: MALTITOL

Excipient focus: PHOSPHORIC ACID

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SODIUM BENZOATE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM LAURYL SULFATE

Excipient focus: SODIUM PHOSPHATE, MONOBASIC

Excipient focus: SORBITOL SOLUTION

Excipient focus: STARCH, CORN

Excipient focus: SUCRALOSE

Excipient focus: TITANIUM DIOXIDE

Excipient focus: WATER

Excipient focus: XYLITOL

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links